Loading...

Home
Stock
APLMW

APLMW News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Forecast Technical Valuation Financials Earnings Should I Buy News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

APLMW News

Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation

Oct 15 2025Newsfilter

Nasdaq Suspends Trading of Apollomics Inc., Ltd.

Sep 17 2025Globenewswire

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 03 2025Newsfilter

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31 2025Newsfilter

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20 2024Newsfilter

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10 2024Newsfilter

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Nov 21 2024Newsfilter

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14 2024Newsfilter

APLMW Events

No data

No data

APLMW Monitor News

No data

No data

APLMW Earnings Analysis

No Data

No Data

People Also Watch